Mark Mannebach

Mark Mannebach has a diverse and extensive work experience in the pharmaceutical industry. Mark is currently serving as the Chief Regulatory Officer at Isosceles Pharmaceuticals since January 2018. Previously, they held the position of Vice President of Regulatory Affairs at Celcuity from April 2022 to June 2023.

Before that, Mark worked at Mallinckrodt Pharmaceuticals for almost nine years, starting in November 2008 and ending in January 2017. Mark held the role of VP Global Regulatory Affairs and was responsible for leading the regulatory affairs function for the company. Mark was also a member of the Executive Management team and Senior Management team.

Prior to their time at Mallinckrodt Pharmaceuticals, Mark was the VP of Regulatory Affairs & Quality Assurance at Santen, Inc from January 2004 to November 2008. Mark played a crucial role in the global regulatory affairs and US quality assurance strategies for the company, focusing on ophthalmology products.

Before joining Santen, Inc, Mark worked as a Regulatory Affairs Director at Pharmacia from January 1999 to January 2004. Mark also worked as an Associate Director of Regulatory Affairs at Baxter Healthcare for a year in 1998, where they developed global regulatory strategies for a blood substitute product.

Mark's career in the pharmaceutical industry began at Parke-Davis Warner-Lambert in July 1989, where they served as a Project Leader/CMC Regulatory until February 1998. Mark also worked as a Program Manager at Marion Laboratories from June 1984 to July 1989 and as a Senior Research Associate at Pennwalt from May 1983 to June 1984.

Overall, Mark Mannebach has held various leadership positions in regulatory affairs throughout their career, contributing to the development and global regulatory strategies of multiple pharmaceutical companies.

Mark Mannebach has a Bachelor of Science (BS) degree in Pharmacy from Wayne State University. Mark further pursued their education and obtained a Master's degree in Chemical Engineering from the University of Detroit. Finally, they completed their education by obtaining a PhD in Pharmacy Administration from the University of Michigan.